var data={"title":"Alprostadil: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alprostadil: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5594?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alprostadil-drug-information\" class=\"drug drug_general\">see &quot;Alprostadil: Drug information&quot;</a> and <a href=\"topic.htm?path=alprostadil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alprostadil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708622\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Apnea (Prostin VR Pediatric): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Apnea is experienced by about 10% to 12% of neonates with congenital heart defects treated with alprostadil pediatric sterile solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, monitor respiratory status throughout treatment, and use alprostadil pediatric injection where ventilatory assistance is immediately available.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132167\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Caverject;</li>\n      <li>Caverject Impulse;</li>\n      <li>Edex;</li>\n      <li>Muse;</li>\n      <li>Prostin VR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132168\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Alprostadil Injection USP;</li>\n      <li>Caverject;</li>\n      <li>Muse Pellet;</li>\n      <li>Prostin VR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050909\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Prostaglandin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12706651\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ductus arteriosus patency, maintenance</b>: Continuous IV infusion: Initial: 0.05 to 0.1 mcg/kg/minute; once therapeutic response is achieved, reduce rate to lowest effective dosage; with unsatisfactory response, increase rate gradually; usual maintenance: 0.01 to 0.4 mcg/kg/minute; higher doses may be required in patients receiving ECMO support (Stone 2006); apnea may be less likely to occur at doses &lt;0.015 mcg/kg/minute (Browning Carmo 2007). <b>Note:</b> Therapeutic response is indicated by an increase in systemic blood pressure and pH in those with restricted systemic blood flow and acidosis, or by an increase in oxygenation (pO<sub>2</sub>) in those with restricted pulmonary blood flow.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050903\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=alprostadil-drug-information\" class=\"drug drug_general\">see &quot;Alprostadil: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Ductus arteriosus patency, maintenance</b>: Infants: Continuous IV infusion: Initial: 0.05 to 0.1 mcg/kg/minute; once therapeutic response is achieved, reduce rate to lowest effective dosage; with unsatisfactory response, increase rate gradually; usual maintenance: 0.01 to 0.4 mcg/kg/minute.<b> Note:</b> Therapeutic response is indicated by an increase in systemic blood pressure and pH in those with restricted systemic blood flow and acidosis, or by an increase in oxygenation (pO<sub>2</sub>) in those with restricted pulmonary blood flow.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132144\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intracavernosal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caverject Impulse: 10 mcg [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caverject Impulse: 20 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Edex: 10 mcg, 20 mcg, 40 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pellet, Urethral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Muse: 125 mcg (1 ea, 6 ea); 250 mcg (1 ea, 6 ea); 500 mcg (1 ea, 6 ea); 1000 mcg (1 ea, 6 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prostin VR: 500 mcg/mL (1 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intracavernosal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caverject: 20 mcg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caverject: 20 mcg (1 ea); 40 mcg (1 ea) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132129\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050912\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous IV infusion: Administer into a large vein or alternatively through an umbilical artery catheter placed at the ductal opening.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by concentration (mcg/mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471276\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471275\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 mcg/mL <b>or</b> 20 mcg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132161\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caverject Impulse: Store unreconstituted product at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Following reconstitution, store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F) and use within 24 hours (do not freeze). Discard any unused solution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caverject powder: Store 20 mcg vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Store 40 mcg vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) until dispensed. After dispensing, stable for up to 3 months at or below 25&deg;C (77&deg;F). Following reconstitution, all strengths should be stored at or below 25&deg;C (77&deg;F); do not refrigerate or freeze; use within 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edex: Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Muse: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); may be stored at room temperature (below 30&deg;C [86&deg;F]) for up to 14 days. Do not expose to temperatures &gt;30&deg;C (86&deg;F). Each system is for single use only; discarded after use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostin VR Pediatric: Refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). The following stability information has also been reported: May be stored at 20&deg;C for up to 34 days or 30&deg;C for up to 26 days (Cohen 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050911\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostin VR Pediatric: Temporary maintenance of patency of ductus arteriosus in neonates with ductal-dependent congenital heart disease until surgery can be performed (FDA approved in neonates)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caverject, Caverject Impulse: Diagnosis (adjunct to other diagnostic tests) and treatment of erectile dysfunction (FDA approved in adult males)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edex, Muse: Treatment of erectile dysfunction (FDA approved in adult males)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132214\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Alprostadil may be confused with alPRAZolam</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prostin VR may be confused with Prostin E2 (dinoprostone)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132212\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraurethral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Penile pain, testicular pain, urethral bleeding (minor), urethral burning, vulvovaginal pruritus (female partner)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracavernosal injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Penile disease, penile pain, penile rash, penile swelling, prolonged erection (&gt;4 hours), Peyronie&rsquo;s disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bruising at injection site, hematoma at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Balanitis, injection site hemorrhage, priapism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia, cardiac arrest, edema, flushing, hypertension, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, headache, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local pain (in structures other than the injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, cough, flu-like symptoms, nasal congestion, sinusitis, upper respiratory infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Anemia, anuria, bradypnea, cardiac failure, cerebral hemorrhage, gastroesophageal reflux disease, hematuria, hemorrhage, hyperbilirubinemia, hyperemia, hyperirritability, hyperkalemia, hypoglycemia, hypothermia, neck hyperextension, peritonitis, second degree atrioventricular block, shock, supraventricular tachycardia, thrombocytopenia, ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132150\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intracavernous: Hypersensitivity to alprostadil or any component of the formulation; conditions predisposing men to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia); men with anatomical deformation or fibrotic conditions of the penis (eg, angulation, cavernosal fibrosis, or Peyronie disease); penile implants</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transurethral: Hypersensitivity to alprostadil or any component of the formulation; urethral stricture, balanitis, severe hypospadias and curvature, and in men with acute or chronic urethritis; men who are prone to venous thrombosis or who have a hyperviscosity syndrome (eg, sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma) predisposing them to priapism; use in men for whom sexual activity is inadvisable; sexual intercourse with a pregnant woman unless a condom barrier is being used</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Documentation of allergenic cross-reactivity for prostaglandins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132133\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Apnea: <b>[US Boxed Warning]: Prostin VR Pediatric: Apnea may occur in 10% to 12% of neonates with congenital heart defects, especially in those weighing &lt;2 kg at birth.</b> Apnea usually appears during the first hour of drug infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Intracavernous injections can increase peripheral blood levels of alprostadil, resulting in hypotension. Syncope has also been reported. Avoid use in men with known cavernosal venous leakage. Patients must be cautioned to avoid tasks such as operating machinery or driving following administration where injury could result if hypotension or syncope were to occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Penile fibrosis: May occur when used for erectile dysfunction; discontinue use in men who develop penile angulation or cavernosal fibrosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism/prolonged erection: May occur when used for erectile dysfunction; instruct patient to seek immediate medical assistance if an erection persists &ge;4 hours; discontinue therapy if priapism or prolonged erection occurs or if signs of penile fibrosis develop (penile angulation, cavernosal fibrosis, or Peyronie disease). To minimize the chances of prolonged erection or priapism, titrate slowly to the lowest effective dose. Use is contraindicated in men who have conditions that predispose them to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia). Underlying causes of erectile dysfunction should be evaluated and treated prior to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Treatment for erectile dysfunction should not be used in men whom sexual activity is inadvisable because of underlying cardiovascular status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Prostin VR Pediatric: Use with caution in neonates with bleeding tendencies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Muse: Urethral abrasion resulting in minor bleeding or spotting may occur from improper administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Needle breakage: Caverject and Caverject Impulse: A superfine needle is used for administration. Needle breakage (a portion of the needle remaining in the penis) has been reported; hospitalization and surgical removal may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patency of ductus arteriosus: Appropriate use: Prostin VR Pediatric: Infuse for the shortest time at the lowest dose consistent with good patient care. Use for &gt;120 hours has been associated with antral hyperplasia and gastric outlet obstruction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46075934\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Alprostadil should not be used in neonates with respiratory distress syndrome; full diagnostic workup should be done to differentiate between respiratory distress syndrome and cyanotic heart disease. Cortical proliferation of long bones has been associated with long-term infusions of alprostadil; most cases of bone changes occurred 4 to 6 weeks after starting alprostadil, but has occurred as early as 9 days. In a study of 86 infants awaiting cardiac transplant, the incidence of hyperostosis was 42% at &lt;30 days of alprostadil infusion, 87% at 30 to 60 days and 100% at &gt;60 days. Cortical hyperostosis usually resolves over 6 to 12 months after stopping alprostadil (Kaufman 1996; Woo 1994).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298715\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132138\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13353&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of Alprostadil.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132140\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (Muse) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132153\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Alprostadil is not indicated for use in women. The manufacturer of Muse recommends a condom barrier when being used during sexual intercourse with a pregnant woman. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050908\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Arterial pressure, respiratory rate, heart rate, temperature, pO<sub>2</sub>; monitor for gastric obstruction in patients receiving PGE<sub>1</sub> for longer than 120 hours; x-rays may be needed to assess cortical hyperostosis in patients receiving prolonged PGE<sub>1</sub> therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132132\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Causes vasodilation by means of direct effect on vascular and ductus arteriosus smooth muscle; relaxes trabecular smooth muscle by dilation of cavernosal arteries when injected along the penile shaft, allowing blood flow to and entrapment in the lacunar spaces of the penis (ie, corporeal veno-occlusive mechanism)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132149\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Erectile dysfunction: 5 to 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Ductus arteriosus will begin to close within 1 to 2 hours after drug is stopped; Erectile dysfunction: Intended duration &lt;1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Insignificant following penile injection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 81% to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: IV: ~70% to 80% by oxidation during a single pass through the lungs; metabolite (13,14 dihydro-PGE<sub>1</sub>) is active and has been identified in neonates </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 30 seconds to 10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acyanotic congenital heart disease: Usual: 1.5 to 3 hours; Range: 15 minutes to 11 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyanotic congenital heart disease: Usual: ~30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erectile dysfunction: Intracavernosal 30 to 60 minutes; Transurethral: ~16 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (90% as metabolites) within 24 hours; feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050917\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Other dosage forms of alprostadil [Caverject injection, Caverject Impulse injection, Edex injection, and Muse Pellet (urethral)] are indicated for the diagnosis and treatment of erectile dysfunction in adult males; see package inserts for further information for this use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132152\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Caverject Impulse Intracavernosal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg (1): $92.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg (1): $119.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Edex Intracavernosal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg (1): $144.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg (1): $186.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg (1): $254.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pellet</b> (Muse Urethral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (1): $70.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (1): $74.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg (1): $79.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg (1): $85.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Alprostadil Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (1 mL): $130.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Prostin VR Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (1 mL): $142.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Caverject Intracavernosal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg (1): $118.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg (1): $155.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132154\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alostin (KR);</li>\n      <li>Alprostan (RU, UA);</li>\n      <li>Alprostapint (BG, HU, VN);</li>\n      <li>Caverject (AE, AR, AT, BB, BH, BM, BO, BR, BS, BZ, CL, CO, CR, CY, DE, DO, EC, EE, EG, ES, FR, GB, GT, GY, HU, IE, IQ, IR, IS, JM, JO, KR, KW, LB, LU, LV, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PR, PT, PY, QA, SA, SE, SG, SI, SR, SV, SY, TR, TT, TW, UY, VE, VN, YE, ZA);</li>\n      <li>Caverject Dual Chamber (FR, HK);</li>\n      <li>Caverject Impulse (AU);</li>\n      <li>Caverjet (IL);</li>\n      <li>Edex (FR);</li>\n      <li>Eglandin (KR);</li>\n      <li>Gaverject (PK);</li>\n      <li>Liple (JP);</li>\n      <li>Minprog (AT);</li>\n      <li>Muse (AE, BH, CY, EG, ES, GB, IE, IQ, IR, JO, KW, LB, LT, LV, LY, OM, QA, SA, SY, YE, ZA);</li>\n      <li>Palux (JP);</li>\n      <li>Pridax (RO);</li>\n      <li>Prink (KR);</li>\n      <li>Promostan (TW);</li>\n      <li>Prostandin (JP, KR);</li>\n      <li>Prostavasin (AE, AR, BR, CN, CR, CY, DO, EG, GT, HN, HU, JO, KW, LU, MX, NI, PA, PH, SK, SV, UY);</li>\n      <li>Prostin Pediatrico (CL);</li>\n      <li>Prostin VR (AE, AU, BE, BH, CH, CO, CY, EG, GB, GR, HN, HR, HU, IL, IN, IQ, IR, IT, JO, KW, LB, LU, LY, NL, NZ, OM, PL, QA, SA, SY, TH, TW, YE, ZA);</li>\n      <li>Prostin VR Paedeatric (MY);</li>\n      <li>Prostin VR Pediatric (HK);</li>\n      <li>Prostine VR (FR);</li>\n      <li>Prostivas (DK, FI, NO, SE);</li>\n      <li>Vazostenon (UA);</li>\n      <li>Viridal (DE, IE);</li>\n      <li>Virilan (AT);</li>\n      <li>Vitaros (GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Browning Carmo KA, Barr P, West M, et al, &quot;Transporting Newborn Infants With Suspected Duct Dependent Congenital Heart Disease on Low-Dose Prostaglandin E1 Without Routine Mechanical Ventilation,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2007, 92(2):F117-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/16905574/pubmed\" target=\"_blank\" id=\"16905574\">16905574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caverject (alprostadil) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caverject Impulse (alprostadil) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edex (alprostadil) [prescribing information]. Lake Forest, IL: Actient Pharmaceuticals, LLC; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaufman MB and El-Chaar GM, &ldquo;Bone and Tissue Changes Following Prostaglandin Therapy in Neonates,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(3):269-74, 277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/8833563/pubmed\" target=\"_blank\" id=\"8833563\">8833563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis AB, Freed MD, Heymann MA, et al, &ldquo;Side Effects of Therapy With Prostaglandin E<sub>1</sub> in Infants With Critical Congenital Heart Disease,&rdquo; <i>Circulation</i>, 1981, 64(5):893-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/7285304/pubmed\" target=\"_blank\" id=\"7285304\">7285304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muse (alprostadil) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peled N, Dagan O, Babyn P, et al, &ldquo;Gastric-Outlet Obstruction Induced by Prostaglandin Therapy in Neonates,&rdquo; <i>N Engl J Med</i>, 1992, 327(8):505-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/1635565/pubmed\" target=\"_blank\" id=\"1635565\">1635565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prostin VR Pediatric (alprostadil) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone DM, Frattarelli DA, Karthikeyan S, et al, &quot;Altered Prostaglandin E1 Dosage During Extracorporeal Membrane Oxygenation in a Newborn With Ductal-Dependent Congenital Heart Disease,&quot; <i>Pediatr Cardiol</i>, 2006, 27(3):360-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/16565906/pubmed\" target=\"_blank\" id=\"16565906\">16565906</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woo K, Emery J, and Peabody J, &ldquo;Cortical Hyperostosis: A Complication of Prolonged Prostaglandin Infusion in Infants Awaiting Cardiac Transplantation,&rdquo; <i>Pediatrics</i>, 1994, 93(3):417-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-pediatric-drug-information/abstract-text/8115200 /pubmed\" target=\"_blank\" id=\"8115200 \">8115200 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13353 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708622\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F132167\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F132168\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050909\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12706651\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050903\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132144\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F132129\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050912\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14471276\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471275\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F132161\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050911\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132214\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132212\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132150\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132133\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46075934\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298715\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132138\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F132140\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F132153\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050908\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132132\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F132149\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1050917\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F132152\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132154\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13353|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alprostadil-drug-information\" class=\"drug drug_general\">Alprostadil: Drug information</a></li><li><a href=\"topic.htm?path=alprostadil-patient-drug-information\" class=\"drug drug_patient\">Alprostadil: Patient drug information</a></li></ul></div></div>","javascript":null}